

Cardiac Therapy Emerges as the Strongest Growth Driver of IPM in MAT December 2025: Pharmarack

19 January 2026 | News

The cardiac segment has delivered a double-digit five-year CAGR



The Indian pharmaceutical market (IPM) continues to demonstrate robust growth, with the Cardiac therapy segment emerging as the strongest performer in MAT December 2025, according to Pharmarack Technologies. Driven by the rising burden of non-communicable diseases (NCDs), earlier diagnosis and longer treatment duration, the Cardiac segment has delivered a double-digit five-year CAGR, reinforcing its leadership position within the Indian pharma landscape.

In a presentation on Highlights of 2025 and what 2026 has in store for IPM, Sheetal Sapale, Vice President – Commercial, Pharmarack Technologies said that the Cardiac market, valued at Rs 33,115 crore, recorded 11 per cent value growth in MAT December 2025 (five-year CAGR), supported by healthy volume and price expansion. While anti-hypertensives remain the largest sub-therapy with around 49 per cent share, their contribution has moderated from over 60 per cent a decade ago, reflecting diversification and faster growth in other cardiac sub-segments. Anti-hypertensives were valued at Rs 16,371 crore with 10 per cent growth, lipid-lowering drugs at Rs 7,646 crore with 14 per cent growth, heart failure therapies at Rs 1,519 crore with 17 per cent growth, diuretics at Rs 1,496 crore with 19 per cent growth, platelet aggregation inhibitors at Rs 1,670 crore with 12 per cent growth, while varicose therapy emerged as the fastest-growing niche with 15 per cent value growth.

All major sub-segments within the Cardiac category posted strong growth, reflecting increased diagnosis of hypertension, dyslipidaemia and heart failure, along with improved chronic therapy compliance and greater specialist-driven care. The market also witnessed six significant new molecule and combination launches in the last two years, including Inclisiran, Edoxaban, Centhaquine, Azelnidipine plus Metoprolol, Bisoprolol plus Perindopril Arginine, and Valsartan plus Sacubitril plus Dapagliflozin, further strengthening therapy depth and innovation.

Looking ahead to 2026, Cardiac therapy growth is expected to remain robust, supported by a younger at-risk population, rising disease awareness and longer treatment duration. Commenting on the outlook, Sheetal Sapale said that the Cardiac therapy segment has clearly emerged as the strongest growth engine of the Indian pharma market, with broad-based growth across sub-therapies and sustained momentum expected to continue into 2026, driven by innovation, deeper diagnosis and improved chronic compliance.